Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 23 Issue 4, April 2005

Editorial

Top of page ⤴

News

  • Although the financial implications of Elan's and Biogen Idec's shock withdrawal from the market of the highly promising multiple sclerosis drug Tysabri were immediate and dramatic, it could have long-term consequences on the whole class of drug as companies developing drugs with a similar mechanism of action as Tysabri had to suspend their trials.

    • Cormac Sheridan
    News
  • For the past 40 years, there has been no major addition to the repertoire of drugs for treating severe, chronic pain. Now, two drugs with a completely different mechanism of action, targeting N-type calcium channels, are making their market debuts in the US and Europe—milestones that have received remarkably little attention.

    • Ken Garber
    News
  • Australia's biotech sector has no shortage of good ideas with a total of 30 new companies listing on ASX over the past 20 months. But with too many immature companies, and not enough sophisticated investors, the sector is struggling to achieve stability and growth.

    • Graeme O'Neill
    News
  • Monsanto recently acquired a US fruit and vegetable seed outfit, a move that both Wall Street analysts and environmental activists (oddly) agree could spell trouble.

    • Stephan Herrera
    News
Top of page ⤴

News in Brief

Top of page ⤴

News

  • Veterinarian Lester Crawford has been nominated to be Commissioner of the US Food and Drug Administration. Can he provide the agency with the leadership it so desperately needs?

    • Jeffrey L. Fox
    News
Top of page ⤴

Data Page

Top of page ⤴

News Feature

  • Surging numbers of therapeutic proteins and small molecules, rationally designed to trigger cell death, are entering the clinic against cancer. In theory, they should provide an entirely new kind of targeted therapy, but troubling questions of basic biology remain.

    • Ken Garber
    News Feature
Top of page ⤴

Correspondence

Top of page ⤴

Commentary

Top of page ⤴

Investors Lab

Top of page ⤴

Book Review

Top of page ⤴

Feature

  • A lesser known valuation approach for biopharmaceutical products offers project managers and out-licensing biotech companies an edge in budget and license negotiations.

    • Ralph Villiger
    • Boris Bogdan
    Feature
Top of page ⤴

News & Views

  • A more nutritious version of Golden Rice may offer a practical solution to vitamin A deficiency.

    • Michael A Grusak
    News & Views
  • Transgenic cows expressing an antibacterial endopeptidase in their mammary glands show enhanced resistance to mastitis.

    • Pascal Rainard
    News & Views
  • Genetic engineering promises to improve a technique for controlling medflies that avoids chemical insecticides.

    • Ernst A Wimmer
    News & Views
  • Injured tissues in aged animals are regenerated by exposure to young serum.

    • Hans-Willem Snoeck
    News & Views
Top of page ⤴

Perspective

Top of page ⤴

Article

Top of page ⤴

Letter

Top of page ⤴

Erratum

Top of page ⤴

Corrigendum

Top of page ⤴

Patents

Top of page ⤴

New on the Market

Top of page ⤴

Commentary

Top of page ⤴

Careers and Recruitment

Top of page ⤴

People

Top of page ⤴

Search

Quick links